Regeneron Pharmaceuticals Inc (REGN)
Nasdaq · Common stock · Pharmaceutical Preparations
As of Oct 21, 2:18 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow REGN in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on REGN and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
REGN at a glance
Key statistics
$83.13B
Market capitalization
- Previous close
- $807.48
- Open
- $801.52
- Day range
- $800.75 – $813.32
- Volume
- 308.0K
- Average volume (30 sessions)
- 719.4K
- Shares outstanding
- 101.14M
- Price / earnings
- 19.2
- Earnings per share
- $42.04
- Price / book
- 2.6
- Price / sales
- 5.3
- Dividend yield
- 0.46%
- Beta (1 year, vs SPY)
- 0.49
Where the price sits in its year
52-week range
81% of the range
- Below the 52-week high
- -6.3%
- Above the 52-week low
- +40.6%
Completed sessions through Oct 20, 2026
Technical snapshot
Above its 50-day and 200-day averages
- 20-day average
- $764.06+5.7%
- 50-day average
- $790.80+2.1%
- 200-day average
- $735.62+9.8%
Between the conventional 30 and 70 bands.
+7.2%
1 week
+1.2%
1 month
+24.0%
3 months
+4.6%
Year to date
+39.7%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with REGN
REGN on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on REGN.
See the plans →
Every planScreen names like REGN
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on REGN
Put REGN on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on REGN
See whether there is an open premium alert on REGN, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
REGN headlines
- Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
GlobeNewswire Inc. · Oct 6, 2026
SEC Form 4, most recent first
Insider filings
MURPHY ANDREW J
−380
Co-Chief Scientific Officer · Open-market sale
$296.24K · Oct 14, 2026
MURPHY ANDREW J
−6
Co-Chief Scientific Officer · Open-market sale
$4.52K · Oct 14, 2026
MURPHY ANDREW J
−211
Co-Chief Scientific Officer · Open-market sale
$163.01K · Oct 14, 2026
MURPHY ANDREW J
−192
Co-Chief Scientific Officer · Open-market sale
$147.34K · Oct 14, 2026
MURPHY ANDREW J
−74
Co-Chief Scientific Officer · Open-market sale
$56.29K · Oct 14, 2026
MURPHY ANDREW J
−16
Co-Chief Scientific Officer · Open-market sale
$12.12K · Oct 14, 2026
MURPHY ANDREW J
−55
Co-Chief Scientific Officer · Open-market sale
$41.94K · Oct 14, 2026
MURPHY ANDREW J
−279
Co-Chief Scientific Officer · Open-market sale
$213.85K · Oct 14, 2026
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Pharmaceutical Preparations
- Headquarters
- Tarrytown, NY
- Employees
- 15,410
- Listed since
- Apr 2, 1991
- Website
- regeneron.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.